Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice
- 1Department of Pharmacology, College of Pharmacy, Al-Esraa University, Baghdad, Iraq.
- 2Department of Clinical Pharmacy, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq.
- 3Department of Pharmacology, College of Health and Medical Technology, Uruk University, Baghdad, Iraq.
- 0Department of Pharmacology, College of Pharmacy, Al-Esraa University, Baghdad, Iraq.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Dapagliflozin shows anti-aging benefits in mice by reducing inflammation and improving antioxidant function. This study highlights its potential to mitigate age-related physiological decline.
Area Of Science
- Gerontology and Pharmacology
- Biomedical Research on Aging
Background
- Aging is a complex biological process with significant research interest in interventions.
- Developing strategies to slow aging and improve healthspan is a key scientific goal.
Purpose Of The Study
- To evaluate the anti-aging effects of dapagliflozin (DAPA) in a D-galactose-induced aging mouse model.
- To assess DAPA's impact on inflammatory markers and antioxidant efficacy.
Main Methods
- Forty male Swiss albino mice were used, divided into control, aging model, Vitamin C, and dapagliflozin groups.
- Aging was induced using D-galactose; treatments included saline, Vitamin C, and dapagliflozin.
- Key aging biomarkers such as inflammatory mediators (TNF-α, IL-1β) and glutathione peroxidase (GSH-Px) were measured.
Main Results
- Dapagliflozin treatment significantly reduced inflammatory mediators (TNF-α, IL-1β) compared to the aging model group.
- No significant difference in inflammatory mediators or GSH-Px was observed between Vitamin C and dapagliflozin groups.
- Dapagliflozin demonstrated beneficial effects including reduced cardiomyocyte hypertrophy, improved skin vitality, and enhanced antioxidant efficacy.
Conclusions
- Dapagliflozin exhibits significant anti-aging properties in a mouse model.
- The drug effectively mitigates key aging indicators, including inflammation and oxidative stress.
- Dapagliflozin represents a potential therapeutic agent for combating age-related physiological changes.
Keywords:
AGEs, Advanced Glycation End Products CVD, Cardiovascular Disease Ca2+, Calcium Col-I, Collagen I Col-III, Collagen III DAPA, Dapagliflozin Dapagliflozin GSH-Px, Glutathione Peroxidase H&E, Hematoxylin and Eosin Stain HPF, High Power Fields IL-1β, Interleukin-1 Beta IP, Intraperitoneally MDA, Malondialdehyde ROS, Reactive Oxygen Species SD, Standard Deviation SGLT2, Sodium-Glucose Cotransporter-2 SGLT2i, Sodium-Glucose Cotransporter 2 Inhibitors TNF-α, Tumor Necrosis Factor-Alpha aging heart inflammation oxidative stress skin
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

